Panitumumab Pregnancy and Breastfeeding Warnings
Panitumumab is also known as: Vectibix
Panitumumab Pregnancy Warnings
Panitumumab has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of embryolethality and abortifacient effects. There are no controlled data in human pregnancy. Panitumumab should only be given during pregnancy when there are no alternatives and benefit outweighs risk. In women of childbearing potential, appropriate contraceptive measures must be used during treatment with panitumumab and for six months following the last dose of panitumumab.
Human IgG is known to cross the placental barrier. Therefore, panitumumab may be transmitted from the mother to the developing fetus. If panitumumab is used during pregnancy or the patient becomes pregnant while receiving the drug, she should be apprised of the potential risk for loss of the pregnancy or potential hazard to the fetus.
Panitumumab Breastfeeding Warnings
Published data suggest that breast milk antibodies do not enter the neonatal and infant circulation in substantial amounts.
There are no data on the excretion of panitumumab into human milk. Because human IgG is secreted into human milk, panitumumab might also be secreted. Women must be advised to discontinue nursing during treatment with panitumumab and for two months after the last dose of panitumumab.
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.